PROPANC BIOPHARMA, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
PROPANC BIOPHARMA, INC. (PPCB) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $10.23 thousand for the 12-month period ending 2025-06-30, per its S-1 filed 2026-07-17.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2026-07-17
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2025-03-31 was $893.00, a 98.87% decline year-over-year.
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2024-09-30 was $9.34K, a 73.20% decline year-over-year.
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2024-03-31 was $79.23K, a 40.43% decline year-over-year.
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2023-12-31 was $52.47K, a 38.52% decline year-over-year.
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2023 was $411.11K, a 22.47% increase from fiscal 2022.
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2022 was $335.68K.
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2021 was -$11.79K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|---|
| 2025-06-30 | $10.23K S-1 · filed 2026-07-17 | |||
| 2025-03-31 | $893.00 S-1 · filed 2026-07-17 | |||
| 2024-09-30 | $9.34K S-1 · filed 2026-07-17 | |||
| 2024-06-30 | $246.25K S-1 · filed 2026-07-17 | |||
| 2024-03-31 | $79.23K 10-Q · filed 2025-05-15 | $131.70K derived: sum of 2 quarters · filed 2025-05-15 | $166.53K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $52.47K 10-Q · filed 2025-05-15 | $87.31K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-09-30 | $34.84K 10-Q · filed 2025-05-15 | |||
| 2023-06-30 | $411.11K 10-K · filed 2024-09-30 | |||
| 2023-03-31 | $133.00K 10-Q · filed 2024-05-15 | $218.35K derived: sum of 2 quarters · filed 2024-05-15 | $351.99K derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | $85.35K 10-Q · filed 2024-05-15 | $218.99K derived: sum of 2 quarters · filed 2024-05-15 | ||
| 2022-09-30 | $133.65K 10-Q · filed 2024-05-15 | |||
| 2022-06-30 | $335.68K 10-K · filed 2023-09-28 | |||
| 2021-06-30 | -$11.79K 10-K · filed 2022-09-28 | |||
| 2020-12-31 | -$11.79K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |